The pharma industry’s R&D concentration has been shifting towards specialty therapy areas as research and development returns decline for some leaders.
The healthcare ad industry continues to thrive and adapt to the new demands for relevance and creativity.
Executives from the 2015 and 2014 Manny Award winners and finalists share their views on a variety of industry-related topics.
The top pharmaceutical companies are blurring the lines with biotech and have been engaging in many collaborations, acquisitions, and restructuring plans in the past year.
Humira during 2014 remained the world’s best-selling prescription medicine; Sovaldi vaulted into second place in its first full year on the market; Harvoni is challenging Humira for the 2015 sales crown.
The U.S. biotechnology arena is undergoing a record-breaking M&A cycle for the industry. After generating M&A activity valued at $235 billion during 2014, the U.S. biotech sector produced more than $100 billion in deals during first-quarter 2015.
As the pipelines of their pharmaceutical and biotech clients continue to yield new drugs for patients, agencies are also seeing their business grow.
Biologic medicines and immunotherapy are front and center amongst many of the R&D strategies and platforms for the industry’s leading developers.
The industry’s patent cliffs have become less steep, but the Affordable Care Act will give pharma new challenges.
Fluidity was the state of pharmaceutical advertising in 2013, as agencies shifted their operations, personnel, and tactics to meet the needs of their clients, driven by the pace of digital.